$1.76 Billion is the total value of Perceptive Advisors's 173 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 158.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBIX | Buy | NEUROCRINE BIOSCIENCES SHARES | $145,771,000 | +13.6% | 3,366,530 | +1.5% | 8.30% | -9.0% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS SHARES | $142,203,000 | +214.5% | 3,858,978 | +23.3% | 8.10% | +152.0% |
| VSAR | Buy | VERSARTIS SHARES | $94,096,000 | +52.0% | 4,407,317 | +6.1% | 5.36% | +21.8% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL SHARES | $63,857,000 | +176.1% | 2,139,274 | +62.2% | 3.64% | +121.2% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS SHARES | $56,553,000 | +1174.9% | 1,103,475 | +831.4% | 3.22% | +922.9% |
| RTRX | Buy | RETROPHIN SHARES | $51,826,000 | +1.9% | 2,807,525 | +4.5% | 2.95% | -18.4% |
| RDUS | Buy | RADIUS HEALTH SHARES | $35,205,000 | +250.8% | 910,872 | +245.2% | 2.00% | +180.8% |
| EVH | Buy | EVOLENT HEALTH SHARES CLASS A | $32,212,000 | +607.2% | 1,444,500 | +369.3% | 1.84% | +466.4% |
| VRTX | Buy | VERTEX PHARMACEUTICALS SHARES | $32,095,000 | +409.5% | 293,509 | +243.2% | 1.83% | +308.0% |
| RGNX | Buy | REGENXBIO SHARES | $26,947,000 | +13.3% | 1,396,244 | +8.9% | 1.54% | -9.2% |
| CTMX | Buy | CYTOMX THERAPEUTICS SHARES | $26,434,000 | +160.4% | 1,530,659 | +65.7% | 1.51% | +108.6% |
| ANAB | New | ANAPTYSBIO SHARES | $24,474,000 | – | 881,957 | +100.0% | 1.39% | – |
| ZGNX | Buy | ZOGENIX SHARES | $23,906,000 | +161.3% | 2,203,302 | +192.6% | 1.36% | +109.2% |
| ARDX | Buy | ARDELYX SHARES | $23,860,000 | -8.5% | 1,886,196 | +2.7% | 1.36% | -26.7% |
| NVRO | New | NEVRO SHARES | $20,360,000 | – | 217,292 | +100.0% | 1.16% | – |
| QTNT | Buy | QUOTIENT SHARES | $20,372,000 | +47.5% | 2,917,785 | +2.2% | 1.16% | +18.1% |
| KDMN | Buy | KADMON SHARES | $18,772,000 | +58.8% | 5,185,847 | +134.7% | 1.07% | +27.1% |
| BPMC | Buy | BLUEPRINT MEDICINES SHARES | $18,461,000 | +140.4% | 461,642 | +68.6% | 1.05% | +92.7% |
| XLRN | Buy | ACCELERON PHARMA SHARES | $17,572,000 | +11.1% | 663,857 | +7.1% | 1.00% | -11.0% |
| AVDL | Buy | AVADEL PHARMACEUTICALS ADR | $13,632,000 | -5.5% | 1,408,240 | +1.4% | 0.78% | -24.3% |
| ALDX | Buy | ALDEYRA THERAPEUTICS SHARES | $12,897,000 | +24.2% | 2,885,458 | +48.7% | 0.74% | -0.4% |
| AMAG | Buy | AMAG PHARMACEUTICALS SHARES | $12,628,000 | +1759.8% | 560,000 | +2768.3% | 0.72% | +1397.9% |
| CORI | New | CORIUM INTERNATIONAL SHARES | $11,096,000 | – | 2,654,485 | +100.0% | 0.63% | – |
| ABMD | Buy | ABIOMED SHARES | $10,642,000 | +88583.3% | 85,000 | +77881.7% | 0.61% | +60500.0% |
| BIO | Buy | BIO RAD LABORATORIES SHARES CLASS A | $9,851,000 | +121.3% | 49,416 | +102.4% | 0.56% | +77.0% |
| EXAS | New | EXACT SCIENCES SHARES | $9,684,000 | – | 410,000 | +100.0% | 0.55% | – |
| CSU | Buy | CAPITAL SENIOR LIVING SHARES | $8,087,000 | +54.9% | 575,173 | +79.6% | 0.46% | +24.3% |
| CDTX | Buy | CIDARA THERAPEUTICS SHARES | $6,445,000 | -19.9% | 826,369 | +6.9% | 0.37% | -35.8% |
| VIVE | New | VIVEVE MEDICAL SHARES | $5,942,000 | – | 938,742 | +100.0% | 0.34% | – |
| SRRA | New | SIERRA ONCOLOGY SHARES | $5,667,000 | – | 3,703,704 | +100.0% | 0.32% | – |
| HUM | Buy | HUMANA SHARES | $5,669,000 | +1148.7% | 27,500 | +1134.8% | 0.32% | +909.4% |
| AXGT | New | AXOVANT SCIENCES SHARES | $4,631,000 | – | 310,000 | +100.0% | 0.26% | – |
| SGYPQ | Buy | SYNERGY PHARMACEUTICALS SHARES | $4,558,000 | +52.6% | 978,100 | +99.5% | 0.26% | +22.6% |
| AMGN | New | AMGEN SHARES | $3,281,000 | – | 20,000 | +100.0% | 0.19% | – |
| AVEO | Buy | AVEO PHARMACEUTICALS SHARES | $3,014,000 | +79.6% | 5,108,808 | +64.3% | 0.17% | +44.5% |
| OCRX | New | OCERA THERAPEUTICS SHARES | $2,817,000 | – | 2,150,000 | +100.0% | 0.16% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS SHARES | $2,268,000 | – | 57,870 | +100.0% | 0.13% | – |
| ALQA | Buy | ALLIQUA BIOMEDICAL SHARES | $2,136,000 | +88.5% | 4,233,951 | +120.3% | 0.12% | +50.6% |
| UNH | Buy | UNITEDHEALTH GROUP SHARES | $2,132,000 | +313.2% | 13,000 | +303.4% | 0.12% | +227.0% |
| SAGE | New | SAGE THERAPEUTICS INC REGISTERED SHARES CALL 80 06/16/2017call | $1,966,000 | – | 200,000 | +100.0% | 0.11% | – |
| IMMU | New | IMMUNOMEDICS SHARES | $1,941,000 | – | 300,060 | +100.0% | 0.11% | – |
| BCLI | New | BRAINSTORM CELL THERAPEUTICS INC SHARES (OLD) | $1,700,000 | – | 400,000 | +100.0% | 0.10% | – |
| AXGT | New | AXOVANT SCIENCES LTD REGISTERED SHARES CALL 25 10/20/2017call | $1,420,000 | – | 200,000 | +100.0% | 0.08% | – |
| CRIS | New | CURIS SHARES | $1,390,000 | – | 500,000 | +100.0% | 0.08% | – |
| BLCM | New | BELLICUM PHARMACEUTICALS SHARES | $1,064,000 | – | 86,200 | +100.0% | 0.06% | – |
| AKRXQ | New | AKORN SHARES | $963,000 | – | 40,000 | +100.0% | 0.06% | – |
| ZSAN | New | ZOSANO PHARMA SHARES | $950,000 | – | 500,000 | +100.0% | 0.05% | – |
| WCG | Buy | WELLCARE HEALTHCARE PLANS SHARES | $741,000 | +6.9% | 5,283 | +4.5% | 0.04% | -14.3% |
| HSKA | New | HESKA SHARES | $661,000 | – | 6,300 | +100.0% | 0.04% | – |
| OSUR | New | ORASURE TECHNOLOGIES SHARES | $609,000 | – | 47,125 | +100.0% | 0.04% | – |
| AKAOQ | New | ACHAOGEN SHARES | $593,000 | – | 23,496 | +100.0% | 0.03% | – |
| ILMN | New | ILLUMINA SHARES | $597,000 | – | 3,500 | +100.0% | 0.03% | – |
| MASI | New | MASIMO SHARES | $554,000 | – | 5,945 | +100.0% | 0.03% | – |
| RDUS | New | RADIUS HEALTH INC REGISTERED SHARES PUT 30 07/21/2017put | $570,000 | – | 9,800 | +100.0% | 0.03% | – |
| CNC | New | CENTENE SHARES | $551,000 | – | 7,726 | +100.0% | 0.03% | – |
| HMSY | New | HMS HOLDINGS SHARES | $540,000 | – | 26,553 | +100.0% | 0.03% | – |
| MDRX | New | ALLSCRIPTS HEALTHCARE SOLUTIONS SHARES | $545,000 | – | 42,955 | +100.0% | 0.03% | – |
| PRAH | New | PRA HEALTH SCIENCES SHARES | $542,000 | – | 8,308 | +100.0% | 0.03% | – |
| CBM | New | CAMBREX SHARES | $524,000 | – | 9,515 | +100.0% | 0.03% | – |
| MCK | Buy | MCKESSON SHARES | $534,000 | +23.6% | 3,601 | +17.0% | 0.03% | -3.2% |
| VNDA | New | VANDA PHARMACEUTICALS SHARES | $507,000 | – | 36,232 | +100.0% | 0.03% | – |
| PAHC | New | PHIBRO ANIMAL HEALTH SHARES CLASS A | $517,000 | – | 18,382 | +100.0% | 0.03% | – |
| QSII | New | QUALITY SYSTEMS SHARES | $516,000 | – | 33,875 | +100.0% | 0.03% | – |
| ANTM | New | ANTHEM SHARES | $510,000 | – | 3,081 | +100.0% | 0.03% | – |
| CUTR | New | CUTERA SHARES | $496,000 | – | 23,981 | +100.0% | 0.03% | – |
| BLUE | New | BLUEBIRD BIO SHARES | $422,000 | – | 4,644 | +100.0% | 0.02% | – |
| EARS | New | AURIS MEDICAL HOLDING SHARES | $368,000 | – | 400,000 | +100.0% | 0.02% | – |
| New | PERNIX THERAPEUTICS HOLD 01APR21 4.25PCT | $275,000 | – | 1,000,000 | +100.0% | 0.02% | – | |
| ARRY | New | ARRAY BIOPHARMA SHARES | $228,000 | – | 25,510 | +100.0% | 0.01% | – |
| EVH | New | EVOLENT HEALTH INC SHARES -A- CALL 20 06/16/2017call | $190,000 | – | 50,000 | +100.0% | 0.01% | – |
| RCM | New | R1 RCM SHARES | $56,000 | – | 17,976 | +100.0% | 0.00% | – |
| ADHD | New | ALCOBRA SHARES | $10,000 | – | 9,109 | +100.0% | 0.00% | – |
| EPZM | New | EPIZYME SHARES | $20,000 | – | 1,165 | +100.0% | 0.00% | – |
| ABBV | New | ABBVIE SHARES | $25,000 | – | 380 | +100.0% | 0.00% | – |
| CLDX | New | CELLDEX THERAPEUTICS SHARES | $25,000 | – | 6,970 | +100.0% | 0.00% | – |
| CERS | New | CERUS SHARES | $3,000 | – | 740 | +100.0% | 0.00% | – |
| ACHC | New | ACADIA HEALTHCARE COMPANY SHARES | $0 | – | 1 | +100.0% | 0.00% | – |
| XIV | New | CREDIT SUISSE VELOCITYSHARES DAILY INVERSE VIX SHORT TERM ET | $1,000 | – | 16 | +100.0% | 0.00% | – |
| OPHT | New | OPHTHOTECH SHARES | $5,000 | – | 1,600 | +100.0% | 0.00% | – |
| OBLN | New | OBALON THERAPEUTICS SHARES | $0 | – | 4 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
About Perceptive Advisors
Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.
The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.
One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.
Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES SHARES | 42 | Q3 2023 | 15.7% |
| AMICUS THERAPEUTICS SHARES | 39 | Q3 2023 | 14.0% |
| ALDEYRA THERAPEUTICS SHARES | 35 | Q3 2023 | 3.3% |
| QUOTIENT TECHNOLOGY INC | 34 | Q3 2022 | 2.7% |
| GLOBAL BLOOD THERAPEUTICS SHARES | 29 | Q3 2022 | 9.3% |
| ADMA BIOLOGICS SHARES | 29 | Q3 2023 | 1.4% |
| RETROPHIN SHARES | 28 | Q3 2020 | 5.5% |
| DBV TECHNOLOGIES SA-SPON ADR | 28 | Q3 2021 | 1.8% |
| VBI VACCINES SHARES | 27 | Q1 2023 | 2.8% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
View Perceptive Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHEMBIO DIAGNOSTICS, INC.Sold out | May 04, 2023 | 0 | 0.0% |
| VBI Vaccines Inc/BC | April 07, 2023 | 43,509,553 | 16.7% |
| Landos Biopharma, Inc. | March 30, 2023 | 14,869,915 | 47.7% |
| REATA PHARMACEUTICALS INC | March 07, 2023 | 2,083,799 | 6.5% |
| AGILE THERAPEUTICS INCSold out | February 14, 2023 | 0 | 0.0% |
| ALBIREO PHARMA, INC. | February 14, 2023 | 1,757,160 | 8.5% |
| BELLUS Health Inc. | February 14, 2023 | 8,891,027 | 7.1% |
| CinCor Pharma, Inc. | February 14, 2023 | 2,576,325 | 5.9% |
| Coherus BioSciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CONCERT PHARMACEUTICALS, INC. | February 14, 2023 | 1,800,000 | 3.6% |
View Perceptive Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-05-01 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-04-17 |
| 4 | 2024-04-15 |
| SC 13G/A | 2024-04-15 |
| SC 13G | 2024-04-15 |
| SC 13D/A | 2024-04-10 |
| 4 | 2024-04-08 |
| 4 | 2024-04-03 |
| SC 13D/A | 2024-04-03 |
View Perceptive Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.